Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/16/2017 03/17/2017 03/20/2017 03/21/2017 03/22/2017 Date
90.96(c) 90.9(c) 90(c) 87.03(c) 87.42(c) Last
1 798 659 1 003 472 890 847 1 120 126 982 290 Volume
-1.66% -0.07% -0.99% -3.30% +0.45% Change
More quotes
Financials ($)
Sales 2017 1 270 M
EBIT 2017 -154 M
Net income 2017 -168 M
Finance 2017 0,10 M
Yield 2017 -
Sales 2018 1 474 M
EBIT 2018 -39,1 M
Net income 2018 -64,9 M
Finance 2018 61,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,8x
EV / Sales2018 10,2x
Capitalization 15 045 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
03/13 BIOMARIN PHARMACEUTICAL : Technical Reports on Biotech Stocks -- Nektar Therapeu..
03/09 BIOMARIN PHARMACEUTICAL : Studies in the Area of Proinsulin Reported from BioMar..
03/07 BIOMARIN PHARMACEUTICAL : Announces Fourth Quarter and Full Year 2016 Financial ..
03/07 BIOMARIN PHARMACEUTICAL : to Attend Three Investor Conferences in 1Q17
03/07 BIOMARIN TO HOST FOURTH QUARTER AND : 30pm ET
02/27 BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
02/24 BIOMARIN PHARMACEUTICAL : Announces 11 Presentations at 13th Annual WORLDSymposi..
02/23 BIOMARIN PHARMACEUTICAL : reports 4Q loss
02/23 BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
02/15 BIOMARIN PHARMACEUTICAL : Announces 11 Presentations at 13th Annual WORLDSymposi..
More news
Sector news : Biopharmaceuticals
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Biopharmaceuticals
Latest Tweets
03/21Some names near excellent support $FCX $NFX $BBY $YELP $CSC $BMRN
6
03/20Get the latest news and updates for $AMID $JEF $CHEF $BMRN $HZNP automaticall.. 
03/16Insider Selling: BioMarin Pharmaceutical Inc. $BMRN CEO Sells $996,490.00 in .. 
03/15BioMarin Pharmaceutical's outperform rating reiterated at Cowen and Company. .. 
03/13BioMarin Pharmaceutical downgraded by Vetr Inc. to hold. $96.20 PT.  
More tweets
Qtime:81
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/13 Omeros Corporation's Q4 Sales Matter
03/07 Santhera Pharmaceuticals establishes U.S. operations to advance DMD candidate..
03/02 Premarket analyst action - healthcare
02/26 BIOTECH FORUM DAILY DIGEST : Can Aerie Pharmaceuticals Continue To Rally? Spotli..
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 112 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..5.06%15 045
BIOGEN INC5.53%59 557
CSL LIMITED24.55%43 994
ALEXION PHARMACEUTICAL..-2.98%26 662
GRIFOLS SA11.26%14 281
CHONGQING ZHIFEI BIOLO..--.--%4 129
More Results